| 2026-08-07 | Press release | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-29 | Press release | Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults |
| 2026-07-28 | Press release | Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates |
| 2026-07-28 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-28 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-28 | Transcript | Q2 FY26 earnings call transcript |
| Transcript | Q2 FY26 earnings call transcript |
| 2026-07-17 | Press release | Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congr |
| 2026-07-13 | Press release | Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types |
| 2026-07-08 | Press release | Incyte to Report Second Quarter Financial Results · 2026 |
| 2026-07-06 | Press release | Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio |
| 2026-07-06 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-26 | Press release | Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis |
| 2026-06-22 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-19 | Press release | Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| 2026-06-14 | Press release | Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva |
| 2026-06-13 | Press release | Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/ Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival |
| 2026-06-13 | Press release | Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia |
| 2026-06-09 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-08 | Press release | Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders |
| 2026-06-08 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-04 | Press release | Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 |
| 2026-05-30 | Press release | Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL |
| 2026-05-26 | Press release | Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference |
| 2026-05-20 | Press release | Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery |
| 2026-05-19 | Press release | Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development |
| 2026-05-12 | Press release | Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress |
| 2026-05-07 | Press release | Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis |
| 2026-05-06 | Press release | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-01 | Press release | Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease |
| 2026-04-29 | Press release | Incyte to Present at Upcoming Investor Conferences |
| 2026-04-28 | Press release | Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates |
| 2026-04-28 | Press release | Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer |
| 2026-04-28 | Proxy | Definitive proxy statement |
| 2026-04-28 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-28 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-09 | Press release | Incyte to Report First Quarter Financial Results · 2026 |
| 2026-03-30 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-28 | Press release | Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting |
| 2026-03-26 | 8-K | Form 8-K, Item 5.02 |